Form 8-K - Current report:
SEC Accession No. 0001534120-26-000026
Filing Date
2026-04-28
Accepted
2026-04-28 07:01:21
Documents
15
Period of Report
2026-04-26
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K avtx-20260426.htm   iXBRL 8-K 33326
2 EX-10.1 ex-101milestonebuyoutoptio.htm EX-10.1 56550
3 EX-99.1 ex-991almatamilestonerelea.htm EX-99.1 8175
8 GRAPHIC avalo-logoxblk1.jpg GRAPHIC 99614
  Complete submission text file 0001534120-26-000026.txt   388501

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT avtx-20260426.xsd EX-101.SCH 2104
5 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT avtx-20260426_def.xml EX-101.DEF 14550
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT avtx-20260426_lab.xml EX-101.LAB 24544
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT avtx-20260426_pre.xml EX-101.PRE 15065
18 EXTRACTED XBRL INSTANCE DOCUMENT avtx-20260426_htm.xml XML 2629
Mailing Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087
Business Address 1500 LIBERTY RIDGE DRIVE SUITE 321 WAYNE PA 19087 410-522-8707
Avalo Therapeutics, Inc. (Filer) CIK: 0001534120 (see all company filings)

EIN.: 450705648 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37590 | Film No.: 26903081
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)